ES2195785B1 - Nuevos derivados de piridazin-3(2h)-ona. - Google Patents

Nuevos derivados de piridazin-3(2h)-ona.

Info

Publication number
ES2195785B1
ES2195785B1 ES200201111A ES200201111A ES2195785B1 ES 2195785 B1 ES2195785 B1 ES 2195785B1 ES 200201111 A ES200201111 A ES 200201111A ES 200201111 A ES200201111 A ES 200201111A ES 2195785 B1 ES2195785 B1 ES 2195785B1
Authority
ES
Spain
Prior art keywords
piridazin
ona
new derivatives
pyrideazin
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200201111A
Other languages
English (en)
Other versions
ES2195785A1 (es
Inventor
Vittorio Dal Piaz
Maria Paola Giovannoni
Claudia Vergelli
Nuria Aguilar Izquierdo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200201111A priority Critical patent/ES2195785B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to PE2003000462A priority patent/PE20040689A1/es
Priority to CA002485896A priority patent/CA2485896A1/en
Priority to CNB03816342XA priority patent/CN1324014C/zh
Priority to NZ536604A priority patent/NZ536604A/en
Priority to PCT/EP2003/005056 priority patent/WO2003097613A1/en
Priority to KR10-2004-7018292A priority patent/KR20040106536A/ko
Priority to MXPA04011209A priority patent/MXPA04011209A/es
Priority to UA20041210293A priority patent/UA77532C2/uk
Priority to BR0310106-1A priority patent/BR0310106A/pt
Priority to EP03735387A priority patent/EP1503992A1/en
Priority to US10/513,219 priority patent/US7459453B2/en
Priority to UY27807A priority patent/UY27807A1/es
Priority to AU2003236648A priority patent/AU2003236648A1/en
Priority to RU2004136977/04A priority patent/RU2326869C2/ru
Priority to JP2004505346A priority patent/JP2005533024A/ja
Priority to ARP030101684A priority patent/AR040076A1/es
Priority to MYPI20031820A priority patent/MY132106A/en
Priority to TW092113343A priority patent/TWI309981B/zh
Publication of ES2195785A1 publication Critical patent/ES2195785A1/es
Priority to EC2004005410A priority patent/ECSP045410A/es
Priority to ZA200409173A priority patent/ZA200409173B/en
Priority to IL16517304A priority patent/IL165173A0/xx
Priority to NO20045461A priority patent/NO20045461L/no
Publication of ES2195785B1 publication Critical patent/ES2195785B1/es
Application granted granted Critical
Priority to US12/141,712 priority patent/US20080269235A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Nuevos derivados de pirideazin-3(2H)-ona que tiene la estructura química de fórmula general (I) **FIGURA** así como procedimientos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia como inhibidores de fosfodiesterasa 4.
ES200201111A 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona. Expired - Fee Related ES2195785B1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ES200201111A ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.
EP03735387A EP1503992A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
CNB03816342XA CN1324014C (zh) 2002-05-16 2003-05-14 用作pde4抑制剂的哒嗪－3(2h)－酮衍生物、制备方法以及其组合物和用途
NZ536604A NZ536604A (en) 2002-05-16 2003-05-14 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors
PCT/EP2003/005056 WO2003097613A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
KR10-2004-7018292A KR20040106536A (ko) 2002-05-16 2003-05-14 Ｐｄｅ４ 저해제로서의 피리다진-３(２ｈ)-온 유도체
MXPA04011209A MXPA04011209A (es) 2002-05-16 2003-05-14 Derivados de piridazin-3(2h)-ona como inhibidores de pde4.
UA20041210293A UA77532C2 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as phosphodiesterase 4 inhibitors
BR0310106-1A BR0310106A (pt) 2002-05-16 2003-05-14 Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
CA002485896A CA2485896A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
US10/513,219 US7459453B2 (en) 2002-05-16 2003-05-14 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors
UY27807A UY27807A1 (es) 2002-05-16 2003-05-14 Nuevos derivados de piridazin-3(2h)-ona
PE2003000462A PE20040689A1 (es) 2002-05-16 2003-05-14 Nuevos derivados de piridazin-3(2h)-ona
AU2003236648A AU2003236648A1 (en) 2002-05-16 2003-05-14 Pyridazin-3(2h)-one derivatives as pde4 inhibitors
RU2004136977/04A RU2326869C2 (ru) 2002-05-16 2003-05-14 Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
JP2004505346A JP2005533024A (ja) 2002-05-16 2003-05-14 Ｐｄｅ４阻害剤としてのピリダジン−３（２ｈ）−オン誘導体
ARP030101684A AR040076A1 (es) 2002-05-16 2003-05-15 Derivados de piridazin-3(2h)-ona
TW092113343A TWI309981B (en) 2002-05-16 2003-05-16 New pyridazin-3(2h)-one derivatives
MYPI20031820A MY132106A (en) 2002-05-16 2003-05-16 New pyridazin-3(2h)-one derivatives
EC2004005410A ECSP045410A (es) 2002-05-16 2004-11-05 Nuevos derivados de piridazin-3(2h)-ona
ZA200409173A ZA200409173B (en) 2002-05-16 2004-11-11 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors.
IL16517304A IL165173A0 (en) 2002-05-16 2004-11-11 Pyridazin-3(2H)-one derivatives as pde4 inhibitors
NO20045461A NO20045461L (no) 2002-05-16 2004-12-15 Nye pyridazin 3-(2H)-on derivater som PDE4-inhibitorer
US12/141,712 US20080269235A1 (en) 2002-05-16 2008-06-18 Pyridazin-3 (2h) -one derivatives as pde4 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200201111A ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.

Publications (2)

Publication Number Publication Date
ES2195785A1 ES2195785A1 (es) 2003-12-01
ES2195785B1 true ES2195785B1 (es) 2005-03-16

Family

ID=29433276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200201111A Expired - Fee Related ES2195785B1 (es) 2002-05-16 2002-05-16 Nuevos derivados de piridazin-3(2h)-ona.

Country Status (23)

Country Link
US (2) US7459453B2 (es)
EP (1) EP1503992A1 (es)
JP (1) JP2005533024A (es)
KR (1) KR20040106536A (es)
CN (1) CN1324014C (es)
AR (1) AR040076A1 (es)
AU (1) AU2003236648A1 (es)
BR (1) BR0310106A (es)
CA (1) CA2485896A1 (es)
EC (1) ECSP045410A (es)
ES (1) ES2195785B1 (es)
IL (1) IL165173A0 (es)
MX (1) MXPA04011209A (es)
MY (1) MY132106A (es)
NO (1) NO20045461L (es)
NZ (1) NZ536604A (es)
PE (1) PE20040689A1 (es)
RU (1) RU2326869C2 (es)
TW (1) TWI309981B (es)
UA (1) UA77532C2 (es)
UY (1) UY27807A1 (es)
WO (1) WO2003097613A1 (es)
ZA (1) ZA200409173B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2562126A1 (en) * 2004-04-01 2005-10-13 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
BRPI0510486A (pt) * 2004-05-19 2007-11-20 Basf Ag composto, processo para preparar o mesmo, agente pesticida, e, processo para combater fungos nocivos fitopatogênicos
SI1891974T1 (sl) 2004-05-31 2010-11-30 Almirall Sa Kombinacije ki obsegajo antimuskarinska sredstvain PDE innhibitorje
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP2010519204A (ja) * 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
CN104718201A (zh) 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
PL2931275T3 (pl) 2012-12-17 2022-09-05 Almirall S.A. Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
PL3290407T3 (pl) 2013-10-18 2020-09-07 Celgene Quanticel Research, Inc Inhibitory bromodomen
UA124764C2 (uk) 2016-04-15 2021-11-17 Еббві Інк. Інгібітори бромодомену

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2105920B1 (es) 1991-10-09 1998-07-01 Syntex Inc Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.
ES2147841T3 (es) * 1994-01-25 2000-10-01 Nissan Chemical Ind Ltd Derivados de piridazinona.
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
CN1219171A (zh) * 1996-05-20 1999-06-09 达尔文发现有限公司 苯并呋喃甲酰胺及其治疗用途
DE69813895T2 (de) * 1997-11-25 2003-11-06 Warner Lambert Co Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung
WO2000050402A1 (en) * 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
BR0111440A (pt) 2000-06-05 2003-06-03 Altana Pharma Ag Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CICIANI, C. et al.: Synthesis and evaluation of in vitro antitumor activity of some substituted 5-pyridazinyl-styrylketones. Il Farmaco, 1991, Vol. 46, nº (7,8), Páginas 873-885. Tabla I. *
DAL PIAZ et al.: "5-acyl-6-aryl 4 nitro-3(2H)pyridazinones and related 4-amino compounds: Synthesis and pharmacological evaluation". J. of Pharm. Sciences, 1991, Vol. 80, nº 4, páginas 341-348. Tabla III. *

Also Published As

Publication number Publication date
CN1668603A (zh) 2005-09-14
CN1324014C (zh) 2007-07-04
MXPA04011209A (es) 2005-02-14
ECSP045410A (es) 2005-01-03
EP1503992A1 (en) 2005-02-09
TW200400033A (en) 2004-01-01
PE20040689A1 (es) 2004-10-08
ES2195785A1 (es) 2003-12-01
IL165173A0 (en) 2005-12-18
NO20045461L (no) 2005-01-19
JP2005533024A (ja) 2005-11-04
CA2485896A1 (en) 2003-11-27
WO2003097613A1 (en) 2003-11-27
NZ536604A (en) 2006-07-28
ZA200409173B (en) 2005-07-29
AU2003236648A1 (en) 2003-12-02
RU2326869C2 (ru) 2008-06-20
AR040076A1 (es) 2005-03-16
UY27807A1 (es) 2003-11-28
MY132106A (en) 2007-09-28
TWI309981B (en) 2009-05-21
KR20040106536A (ko) 2004-12-17
US20060052379A1 (en) 2006-03-09
UA77532C2 (en) 2006-12-15
US7459453B2 (en) 2008-12-02
RU2004136977A (ru) 2005-07-10
BR0310106A (pt) 2005-02-22
US20080269235A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
UY27760A1 (es) Nuevos derivados de pirrolidinio.
UY27604A1 (es) Compuestos químicos.
UY28342A1 (es) Nuevos compuestos
ECSP045519A (es) Nuevos derivados de quinuclidina-amida
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
SE0202463D0 (sv) Novel compounds
UY28623A1 (es) Derivados de pirazol y usos de los mismos
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY28572A1 (es) Compuestos novedosos
UY28510A1 (es) Compuestos quimicos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
UY27740A1 (es) Nuevos compuestos
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
DE60314623D1 (de) Substituierte pyrazolopyrimidine
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY28694A1 (es) Nuevos compuestos
ECSP045219A (es) Derivados de quinazolinona y su uso como agonistas cb

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2195785B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20101018